DNA - NYSE
Ginkgo Bioworks Holdings, Inc.
$9.83
+5.4%Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
At a Glance
Live SnapshotGinkgo Bioworks Holdings, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Ginkgo Bioworks Holdings, Inc. Cash Flow Statement
DNA • NYSE
| Ginkgo Bioworks Holdings, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-312.8M | -547M | -892.9M | -2.1B | -1.8B | -126.7M | -119.9M | |
59M | 63M | 71.6M | 42.6M | 29.1M | 13.9M | 10.8M | |
-1.4M | -936K | -801K | -14.6M | 30.2M | 0.0 | 54.7M | |
81.5M | 112.3M | 229.9M | 1.9B | 1.6B | 476K | 771K | |
46.6M | 142.7M | 266.9M | -67.4M | -20.9M | 3.1M | -1.6M | |
(0.0) | (894K) | (670K) | (0.0) | (61K) | (0.0) | (31K) | |
-44.1M | -89.7M | 29.8M | -37M | -61.5M | -26.5M | 10.6M | |
-171.1M | -319.6M | -295.5M | -252.2M | -253.8M | -135.8M | -44.7M | |
INVESTING ACTIVITIES | |||||||
-7.7M | -62.5M | -40.8M | -52.3M | -56.5M | -57.8M | -22.2M | |
(0.0) | -5.4M | -38.6M | (26.6M) | -12M | (0.0) | (0.0) | |
-418.6M | (0.0) | (0.0) | -3.7M | -5M | (0.0) | -50.1M | |
185.4M | 4.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
624K | 1.2M | -1.3M | -38.1M | 304K | -9.3M | -2.3M | |
-240.3M | -62.2M | -80.7M | -67.4M | -73.3M | -67.1M | -74.6M | |
FINANCING ACTIVITIES | |||||||
18.1M | 80K | -23K | 99.3M | -25M | 0.0 | -408K | |
-354K | -897K | -1.3M | -1.2M | -1.1M | -748K | 198.6M | |
(0.0) | (0.0) | -23K | (0.0) | -25M | (0.0) | -408K | |
0.0 | -922K | -1.4M | -2.7M | 1.6B | 26K | 7K | |
17.8M | -1.7M | -3.2M | 95.3M | 1.5B | 90.3M | 410.4M | |
CASH FLOW SUMMARY | |||||||
395K | -281K | -588K | 908K | -19K | 0.0 | 0.0 | |
-393.2M | -383.8M | -380M | -223.3M | 1.2B | -112.6M | 291.1M | |
567.4M | 989.6M | 1.4B | 1.6B | 385.9M | 498.5M | 207.4M | |
174.2M | 605.7M | 989.6M | 1.4B | 1.6B | 385.9M | 498.5M | |
-178.7M | -382.1M | -336.3M | -304.5M | -310.3M | -193.7M | -66.9M |
SEC Filings
DNA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 07, 2026 | April 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 27, 2026 | February 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 23, 2025 | December 18, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 |
Related Guides
Continue your DNA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.